Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice (Q38118745)

29 August 2017

title

Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice (English)

1 reference

29 August 2017

4

Dominick J Angiolillo

1 reference

29 August 2017

Ana Muñiz-Lozano

1

1 reference

29 August 2017

Fabiana Rollini

series ordinal

2

1 reference

29 August 2017

Francesco Franchi

series ordinal

3

1 reference

29 August 2017

publication date

1 July 2013

1 reference

Therapeutic advances in cardiovascular disease

29 August 2017

published in

1 reference

29 August 2017

volume

7

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

197-213

1 reference

Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Basic principles of platelet biology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Reperfusion strategies in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

ST-segment resolution and prognosis after facilitated versus primary percutaneous coronary intervention in acute myocardial infarction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Facilitated PCI in patients with ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Molecular regulation of platelet-dependent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Early versus delayed, provisional eptifibatide in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intraveno

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Pathophysiology of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizi

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Bivalirudin for patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Bivalirudin during primary PCI in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Platelet GPIIb-IIIa blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Guidelines on myocardial revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944713487781

21 January 2018

Identifiers

DOI

10.1177/1753944713487781

1 reference

29 August 2017

1 reference